
Role of Ursodeoxycholic Acid in the Prevention of Gallstones …
2023年10月23日 · In our bariatric unit, we prescribe UDCA (650 mg) during the rapid weight-loss period that occurs over the first 6 months after surgery. In conclusion, the use of UDCA in postoperative bariatric patients significantly reduces the …
Primary sclerosing cholangitis: Updates in diagnosis and therapy
Promising regimens are high doses of ursodeoxycholic acid (UDCA) alone or in combination with other drugs, and tacrolimus (FK506). Presently, liver transplantation is the only definitive treatment. The present review will address recent aspects of PSC and focus on pathogenesis, diagnosis and treatment.
Ursodeoxycholic acid in the management of symptomatic …
2023年3月23日 · Ursodeoxycholic acid (UDCA) is a bile acid that dissolves gallstones. There is increasing interest in UDCA for symptomatic gallstones, particularly in those unfit for surgery. A UK clinician survey of use and opinions about UDCA in symptomatic gallstones was performed, assessing clinicians’ beliefs and perceptions of UDCA effectiveness.
Ursodeoxycholic Acid - StatPearls - NCBI Bookshelf
2023年2月12日 · Ursodeoxycholic acid is a medication used to manage and treat cholestatic liver disease. This activity reviews the indications, mechanism of action, and contraindications for UDCA as a valuable agent in managing liver disease.
Ursodeoxycholic acid (Synonyms: 熊去氧胆酸; Ursodeoxycholate; Ursodiol; UDCA)
Ursodeoxycholic acid (Ursodeoxycholate) 是由肠道细菌转化 (cheno) 脱氧胆酸而产生的一种次级胆汁酸,是肠道屏障完整性的关键调节因子,对脂质代谢至关重要。 Ursodeoxycholic acid 作为信号分子,通过与胆汁酸激活的受体相互作用发挥作用,包括 G 蛋白偶联的胆汁酸受体 5 (TGR5, GPCR19) 和法尼酯 X 受体 (FXR)。 Ursodeoxycholic acid 可用于多种肝脏和胃肠道疾病的研究。 Ursodeoxycholic acid 也减少 ACE2 的表达,有助于减少 SARS-CoV-2 感染 。 具有口服活性。 …
熊去氧胆酸:独特的性质和临床应用,Meditsinskiy sovet = Medical …
UDCA能够减少胆固醇向胆汁的分泌,与胆固醇分子形成混合胶束(液晶)并与多功能核受体相互作用,被积极用于治疗和预防胆石症。 UDCA具有刺激肝胆分泌的能力,促进胆管细胞分泌碳酸氢盐,这与原发性胆汁性胆管炎(PBC)和原发性硬化性胆管炎(PSC)患者有关。 UDCA 激活转运蛋白,如胆汁酸输出泵 (BSEP)、多重耐药蛋白 2 (MRP2) – 结合转运蛋白、2 型阴离子交换器 (AE2),并促进它们向细胞小管膜移动。 UDCA 作为一种多效剂,在调节各种细胞类型凋亡的 …
人体熊去氧胆酸代谢及其生物等效性研究的技术挑战_药物
2020年7月9日 · 熊去氧胆酸 (udca)是一种用于胆汁淤积性肝病治疗的重要药物。udca 作为内源性药物的代表,在人体内具有胆汁酸特有的宿主-肠道菌群共代谢和肝-胆-肠循环处置特征,这为其仿制药研发带来了高度的技术挑战。
熊脱氧胆酸 - 百度百科
熊脱氧胆酸(ursodeoxycholic acid,UDCA):它是双羟基胆汁酸,亲水性,在急性和慢性肝炎的应用正在扩大。 胆盐促使水份、卵磷脂、胆固醇和结合胆红素从胆道排泄,熊脱氧胆酸盐比其它胆酸盐有大得多的利胆作用。
Ursodeoxycholic acid for the prevention of symptomatic gallstone ...
2021年10月26日 · The role of ursodeoxycholic acid (UDCA) in cholelithiasis management after one anastomosis gastric bypass (OAGB) for morbid obesity: results of a monocentric randomized controlled trial
Ursodeoxycholic acid | Drugs | BNF | NICE
View ursodeoxycholic acid information, including dose, uses, side-effects, pregnancy, breast feeding, contra-indications and monitoring requirements.
- 某些结果已被删除